Kinetics and metabolism of 2,2-diethylallylacetamide in dog and man

  • H. Uehleke
  • Maria Brinkschulte-Freitas


In dogs, slow intravenous injection of 100 mg of diethylallylacetamide (DA) resulted in maximal blood levels of 10–14 μg/ml, and a rapid phase of elimination during 90 min with a half life of 45 min, followed by a slower elimination rate with a half life of 80–90 min.

After oral application of 30 mg DA/kg to female beagle dogs, maximal blood levels of 14 μg/ml were observed after 90–120 min. The blood concentrations declined with a mean half life of 5 h.

In human volunteers, oral doses of 250 mg DA, or rectal application of 300 mg DA produced highest mean blood levels of 4.8 μg/ml (orally), and 5.4 μg/ml (rectally) after 180 min. The mean blood half life was 7.2 h (orally), and 9.2 h (rectal application). Undesirable effects such as nausea, vomiting, and disorientation began to appear at blood levels above 5 μg/ml.

In the urine of dogs and human volunteers, only 2–3% of unchanged DA was recovered, and less than 1% of 2,2-diethyl-4,5-dihydroxypentanoic acid-γ-lactone (DA-lactone) was identified. Acid hydrolysis of the human urine liberated a total of 14–16% of DA-lactone. This percentage was not increased by splitting the urinary conjugates with glucuronidase and glusulase. Small amounts of 2,2-diethylallylacetic acid, 2,2-diethyl-4-one-pentanoic acid, and 2,2-diethyl-4,5-dihydroxypentanamide were detected.

The new metabolites described were synthetized and fully characterized.

Key words

Diethylallylacetamide Pharmacokinetics Diethylallylacetamide metabolites 2,2-Diethyl-4,5-dihydroxypentanoic acid gamma lactone 2,2-Diethylallylacetic acid 

Abbreviations used in the text




2,2-diethylallylacetamide (2,2-diethyl-4-penteneamide)


2,2-diethylallylacetic acid (2,2-diethyl-4-pentenoic acid)


2,2-diethyl-4,5-dihydroxypentanoic acid-γ-lactone




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bockmühl: Novonal, ein neues Schlafmittel. Chemischer Teil. Dtsch. Med. Wschr.54, 270 (1928)Google Scholar
  2. Breitmaier, E., Jung, G., Voelter, W.: Impuls-Fourier-Transformation-13C-NMR-Spektroskopie, Grundlagen und Anwendungen. Angew. Chem.83, 659–672 (1971)Google Scholar
  3. Brinkschulte, M.: Stoffwechsel von 2,2-Diäthylallylacetamide in vivo und in vitro. Dissertation, Pharmaz. Fakultät, Tübingen 1975Google Scholar
  4. Brinkschulte-Freitas, M., Uehleke, H.: Absorption, distribution and metabolism of 2,2-diethylallylacetamide in dog and man. Naunyn-Schmiedeberg's Arch. Pharmacol.293, Suppl. R 54 (1976)Google Scholar
  5. Doedens, D. J.: Metabolic fate of the porphyrinogenic drug allylisopropylacetamide. Ph.D. Thesis, Univ. of Illinois, U.S.A., 1971. Diss. Abstr.32, 2901–2902 B (1971)Google Scholar
  6. Foreman, R. L., Maynert, E. W.: A tetrahydrofuropyrimidine as a metabolite of secobarbital. Pharmacologist12, 255 (1970)Google Scholar
  7. Goldberg, A., Rimington, C.: Experimentally produced porphyria in animals. Proc. R. Soc. Lond. (Biol.)143, 257–279 (1955)Google Scholar
  8. Harvey, D. J., Glazener, L., Statton, C., Johnson, D. B., Hill, R. M., Horning, E. C., Horning, M. G.: Detection of allyl-substituted barbiturates in rat urine. Res. Comm. Chem. Pathol. Pharmacol.4, 247–260 (1972)Google Scholar
  9. Käferstein, H., Sticht, G.: Intoxikationen mit Novonal. In: V. Schneider: Festschrift zum 65. Geburtstag von W. Krauland, pp. 391–394. Berlin: Univ. Druckerei, F. U. 1977Google Scholar
  10. Leffkowitz, M.: Ein Essigsäureamid (Novonal) als Schlafmittel. Ther. Ggw. 60–62, 1928Google Scholar
  11. Levinger, E.: Novonal als Hypnotikum und Sedativum. Dtsch. Med. Wschr.54, 271–272 (1928)Google Scholar
  12. De Matteis, F.: Drug-induced destruction of cytochrome P-450. Drug Metab. Dispos.1, 267–272 (1973)Google Scholar
  13. Schaumann: Novonal, ein neues Schlafmittel. Pharmakologischer Teil. Dtsch. Med. Wschr.54, 270 (1928)Google Scholar
  14. Smith, A.: The metabolism of 2-allyl-2-isopropylacetamide in vivo and in the isolated perfused rat liver. Biochem. Pharmacol.25, 2429–2442 (1976)Google Scholar
  15. Solheim, E., Scheline, R. R.: Metabolism of alkenebenzene derivatives in the rat. II. Eugenol and isoeugenol methyl ethers. Xenobiotica6, 137–150 (1976)Google Scholar
  16. Stich, W., Decker, P.: Experimentelle Porphyrie durch Derivate substituierter Allylessigsäuren und Pathogenese der menschlichen akuten Porphyrie. Naturwissenschaften42, 161 (1955)Google Scholar
  17. Stillwell, W. G., Carmann, M. J., Bell, L., Horning, M. G.: The metabolism of safrole and 2′,3′-epoxisafrole in the rat and guinea pig. Drug Metab. Disp.2, 489–498 (1974)Google Scholar
  18. Sweeney, G. D., Rothwell, J. D.: Spectroscopic evidence of interaction between 2-allyl-2-isopropylacetamide and cytochrome P-450 of rat liver microsomes. Biochem. Biophys. Res. Commun.55, 798–804 (1973)Google Scholar
  19. Uehleke, H.: The model system of microsomal drug activation and covalent binding to endoplasmic proteins. Proc. Europ. Soc. for the Study of Drug Toxicity, vol. XV, pp. 119–129. Amsterdam: Excerpta Medica Foundation 1973Google Scholar
  20. Uehleke, H., Schnitger, F., Hellmer, K. H.: Verhalten verschiedener Fremdstoff-Oxidationen nach Inaktivierung von Cytochrom P-450 durch UV-Bestrahlung oder durch Desoxycholatbehandlung. Hoppe-Seylers Z. Physiol. Chem.351, 1475–1484 (1970)Google Scholar
  21. Uehleke, H., Tabarelli-Poplawski, S., Bonse, G., Henschler, D.: Spectral evidence for 2,2,3-trichloro-oxirane formation during microsomal trichloroethylene oxidation. Arch. Toxicol.37, 95–105 (1977)Google Scholar
  22. Woldan, L.: Der sedierende Effekt von Diäthylallylacetamid. M. D. Thesis, Med. Fakultät München (1972)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • H. Uehleke
    • 1
  • Maria Brinkschulte-Freitas
    • 1
  1. 1.Pharmakologisches Institut der Universität TübingenTübingenGermany

Personalised recommendations